Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia

Internal Medicine

Volumn 49, Issue 12, 2010, Pages 1195-1200

  Tanaka, Hideo ^a,b   Iwato, Koji ^c   Asou, Hiroya ^b   Kimura, Akiro ^b  

^a HIROSHIMA CITY ASA HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

CEL; FIP1L1; Imatinib; PDGFRA; PRCA

Indexed keywords

HEMOGLOBIN; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; LACTATE DEHYDROGENASE; MIDOSTAURIN; PLATELET DERIVED GROWTH FACTOR A; PREDNISOLONE; PROTEIN FIP1L1; TANESPIMYCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CELL VIABILITY; CHRONIC DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; DYSPLASIA; ENZYME INHIBITION; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; ERYTHROBLAST; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MYELOBLAST; PURE RED CELL ANEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; URTICARIA;

ADULT; CHRONIC DISEASE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RED-CELL APLASIA, PURE;

EID: 77953994932     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3178     Document Type: Article

References (24)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1-27, 1975.
2. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 3: 9, 2001.
3. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26: 881-884, 2002.
4. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 359: 1577-1578, 2002.
5. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214, 2003.
6. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 100: 7830-7835,2003.
7. Swerdlow SH, Campo E, Harris NL, et al., Eds.: WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. IARC, Lyon, 2008.
8. Tanaka H, Ito T, Kyo T, Kimura A. Treatment with IFNα in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Eur J Haematol 78: 389-398,2007.
9. Ito T, Tanaka H, Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 78: 417-431, 2007.
10. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 3: 459-469, 2003.
11. Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22: 1999-2010, 2008.
12. Sada A, Katayama Y, Yamamoto K, et al. A multicenter analysis of the FIP1L1-αPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the αPDGFR exon 12. Ann Hematol 86: 855-863, 2007.
13. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19: 792-798, 2005.
14. Stover EH, Chen J, Folens C, et al. Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent. Proc Natl Acad Sci USA 103: 8078-8083, 2006.
15. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92: 1173-1179, 2007.
16. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104: 3038-3045, 2004.
17. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA ineosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30: 965-970, 2006.
18. Helbig G, Stella-Holowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRAexpressing patients. Br J Haematol 141: 200-204, 2008.
19. Helbig G, Moskwa A, Swiderska A, et al. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up. Br J Haematol 145: 132-134,2009.
20. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109: 4635-4640, 2007.
21. Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 143: 707-715, 2008.
22. Meng HT, Li Y, Jin J, Qian WB, Yang CM. Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib. Ann Hematol 86: 231-232, 2007.
23. Hirri HM, Green PJ. Pure red cell aplasia in a patient with chronic granulocytic leukaemia treated with interferon-α. Clin Lab Haematol 22: 53-54, 2000.
24. Tomita N, Motomura S, Ishigatsubo Y. Interferon-α-induced pure red cell aplasia following chronic myelogenous leukemia. Anticancer Drugs 12: 7-8, 2001.